GlassScriptPhysician profile
Deborah L Sheehan
NPI 1164410353
$1,996.36
in general payments reported to CMS, 2019-2025
26 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $799 · 2021: $567 · 2022: $122 · 2023: $68.05 · 2024: $150 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $344 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $344.24 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $461.94 | 2019-2024 | Airsupra, Farxiga |
| Sanofi US Services INC. | $325.00 | 2021 | |
| Novo Nordisk INC | $178.58 | 2019-2021 | |
| Amgen INC. | $129.06 | 2020-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $127.87 | 2020-2022 | |
| Pfizer INC. | $92.92 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $87.42 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $66.22 | 2020 | |
| Lilly USA, LLC | $63.17 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.38 | 2020-2021 | |
| Genzyme Corporation | $60.00 | 2020 | |
| Collegium Pharmaceutical, INC. | $54.51 | 2020 | |
| Novartis Pharmaceuticals Corporation | $50.54 | 2019-2020 | |
| Eisai INC. | $44.27 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.56 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $28.70 | 2025 | |
| Lundbeck LLC | $19.50 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.93 | 2021 | |
| Esperion Therapeutics, INC. | $14.74 | 2020 | |
| Exact Sciences Corporation | $13.84 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $13.62 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.43 | 2021 | |
| Genentech USA, INC. | $12.42 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $11.91 | 2022 | |
| Phathom Pharmaceuticals, INC. | $2.04 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Sheehan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.